Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

33 results about "Cellular mechanism" patented technology

What is Cellular Mechanism. 1. It involves all those transport ways through which xylem transport heavy metal from soil to different parts of plant including uptake, sequestration and translocation methods.

Novel application of biosensors for diagnosis and treatment of disease

InactiveUS20060160134A1Easy to detectEvaluating efficacyBiological testingAnalyteMedicine
A method for detecting compounds of interest in bodily fluids, including exhaled breath and blood. The present invention uses biosensors that mimic naturally occurring cellular mechanisms, including RNA oligonucleotide chains or “aptamers,” in combination with signaling agents or nanotechnology to provide an effective and efficient method for diagnosing a condition and / or disease within a patient. The subject invention also provides a method for screening those analytes / biomarkers likely to be present in exhaled breath.
Owner:UNIV OF FLORIDA RES FOUNDATION INC

Application of biosensors for diagnosis and treatment of disease

A method for detecting compounds of interest in bodily fluids, including exhaled breath and blood. The present invention uses biosensors that mimic naturally occurring cellular mechanisms, including RNA oligonucleotide chains or “aptamers,” in combination with molecular beacons or nanotechnology to provide an effective and efficient method for diagnosing a condition and / or disease within a patient. The subject invention also provides a method for screening those analytes / biomarkers likely to be present in exhaled breath.
Owner:FLORIDA UNIV OF A FLORIDA

Method to measure the activation state of signaling pathways in cells

The activity of multiple proteins in a single living cell, portion of a cell or in a group of cells is simultaneously measured by introducing reporter molecules. The reporter(s) is chemically modified by the enzyme of interest. In some cases the enzyme(s) is affected by the addition of a stimulus or a pharmaceutical compound to the cell. The reactions between the enzymes and the reporters are diminished or terminated, and the reporter and modified reporter are removed. The activity of the enzyme(s) is determined by measuring the amount of reporter remaining, the amount of altered reporter produced, or by comparing the amount of reporter to the amount of altered reporter. A database is compiled of the activities of the different proteins. By performing a series of experiments at different time points, conditions, and varieties of cell types, a database is developed for molecular cellular mechanisms in health and disease states. By exposing cells to a variety of compounds data for drug development and screening is provided.
Owner:RGT UNIV OF CALIFORNIA

Method to measure the activation state of signaling pathways in cells

The activity of multiple proteins in a single living cell, portion of a cell or in a group of cells is simultaneously measured by introducing reporter molecules into the cell(s) or a portion thereof, chemically modifying the reporter(s) by the enzyme of interest, terminating the modification reactions, removing the reporter(s) and modified reporter(s), and determining the amount of enzyme activity present by measuring or comparing the amount of reporter(s) and modified reporter(s) present. By performing a series of experiments at different time points, conditions, and varieties of cell types, a database is developed for molecular cellular mechanisms in health and disease states. By exposing cells to a variety of compounds data for drug development and screening is provided.
Owner:RGT UNIV OF CALIFORNIA

Method and system for treating obesity-linked diseases by oral administration of active receptor activator

InactiveCN108079317ASimplify treatment effect experimentsLow costCompounds screening/testingDiseaseNovel treatment method
The study is different from other studies in the prior art, and a biological method is used to explore the mechanism of action of AdipoRon on the treatment of type 2 diabetes. Liver cells are used asan experimental subject for construction of an experimental group blocking a P13 / Akt signaling pathway, then the AdipoRon acts, and expression of related carbohydrate genes of the liver cells is analyzed to investigate the cellular mechanism of the AdipoRon on the treatment of the type 2 diabetes. At present, the study is not reported at home and abroad. Almost all methods for treating the type 2diabetes require proper diet and exercise, and produce adverse effects such as hypoglycemia and weight gain, by oral administration of the AdipoRon, excess calorie intake can be safely reduced, and consequence caused by a sedentary lifestyle can be reduced, so that the AdipoRon provides a novel treatment method, a lot of money for purchase of db / db mice and double gene knockout mice can be saved.
Owner:WENZHOU MEDICAL UNIV

Treatment solution and method for preventing posterior capsular opacification by selectively inducing detachment and/or death of lens epithelial cells

A treatment solution used to prevent posterior capsular opacification is applied or introduced into the lens capsular bag before, during, or after cataract surgery. The treatment solution may also be applied to an intraocular lens prior to surgery. The treatment solution comprises an ion transport mechanism interference agent, which either alone or in combination with other treatment agents such as an osmotic stress agent and an agent to establish a suitable pH, selectively induces detachment and / or death of lens epithelial cells such that posterior capsular opacification is prevented. While the ion transport mechanism interference agent is capable of interfering with the cellular mechanisms and cell ion distribution of a broad range of cells, a concentration of agent is selected such that the treatment solution interferes selectively with the cellular mechanisms of lens epithelial cells while leaving other ocular cells substantially unharmed. The treatment solution selectively induces cellular death and / or detachment of lens epithelial cells while other ocular cells and tissue remain substantially unharmed and without lengthy preoperative pre-treatment.
Owner:ZHANG JIN JUN

C-glucosidic ellagitannin compounds for use for altering the supramolecular arrangement of actin and for the treatment of osteoporosis, cancer, bacterial infection and viral infection

The present invention concerns a C-glucosidic ellagitannin compound or a metabolite thereof for use for altering the supramolecular arrangement of actin in an individual suffering from osteoporosis, cancer, bacterial infection, or viral infection. It also pertains to pharmaceutical compositions comprising a C-glucosidic ellagitannin compound and / or metabolites thereof and one or more physiologically acceptable carriers. It finally concerns a C-glucosidic ellagitannin compound or a metabolite thereof, optionally detectably labeled, for in vitro use as a tool for studying cellular mechanisms involving actin, or for detecting F-actin in a cell.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +1

In vitro modelling of haematopoietic stem cell medullary nests: a tool for studying the regulation of haematopoiesis, evaluating the nesting potential of a haematopoietic graft and testing the pharmacotoxicology of medicaments

The present invention relates to a culture support for cultivating hematopoietic stem cells (HSCs) and / or hematopoietic progenitors (HPs), comprising a calcium biomaterial, osteoclasts, endothelial cells and mesenchymatous stem cells (MSCs) and / or osteoblasts and / or adipocytes. The present invention also relates to a method for preparing such a culture support, and an in vitro HSC and / or HP cultivation method. The use of such a culture support for studying cellular mechanisms involved in hematopoiesis and / or differentiation of HSC / HPs and / or for studying the efficacy and / or the toxicity of a medicament candidate is also described.
Owner:ETAT FR MINIST DE LA DEFENSE SERVICE DE SANTE DES ARMEES +1

Methods for reduction of adipose tissue mass

InactiveUS20080200422A1Increase glucose clearanceFaster clearance of glucoseBiocidePeptide/protein ingredientsCellular mechanismAgonist
The present disclosure relates to diets, compounds, e.g., GCN2 agonists and methods that selectively reduce adipose tissue mass relative to the mass of other tissue types and increase insulin sensitivity. Another aspect of the disclosure relates to methods for identifying GCN2 agonists that will decrease the activity and / or expression of one or more of adipogenic genes thereby selectively inhibiting the cellular mechanisms that lead to fat production. Such agonists have the effect of reducing adipose tissue mass in an individual.
Owner:PENN STATE RES FOUND

Pseudocomplementary Oligonucleotides for Targeted Gene Therapy

Compositions and methods for targeted gene therapy are disclosed. Compositions containing double duplex-forming pseudocomplementary oligonucleotides are administered in combination with a donor oligonucleotide that is homologous to a target sequence on a double-stranded DNA molecule in need of repair or replacement. By activating cellular mechanisms involved in DNA synthesis, repair and recombination, the double duplex-forming pseudocomplementary oligonucleotides can introduce one or more mutations at a site of interest by increasing the efficiency of targeted recombination of the donor oligonucleotide. The pseudocomplementary oligonucleotides / donor oligonucleotide compositions may be administered in combination with a second therapeutic agent that enhances access of the pseudocomplementary oligonucleotides and / or the donor oligonucleotide to the target site, an agent that enhances or increases DNA repair or recombination, or an agent that enhances uptake or delivery of the oligonucleotides.
Owner:YALE UNIV

Methods of inhibiting metastasis in cancer

As described herein, a method of inhibiting metastasis in cancer includes administering to a human subject diagnosed with a cancer of an organ of the peritoneal cavity a therapeutically effective amount of an inhibitor of CCR5 or P-selectin. Preferably the subject has a tumor positive for a ligand of P-selectin such as a CD24+ or PSGL-1+ tumor. Analysis of samples from HGSOC patients confirmed increased MIP-1β and P-selectin, suggesting that this novel multi-cellular mechanism can be targeted to slow or stop metastasis in cancers such as high-grade serous ovarian cancer, for example by using anti-CCR5 and P-selectin therapies developed for other indications.
Owner:WISCONSIN ALUMNI RES FOUND

NTDs (neural tube defects) rat embryo animal model and constructing method thereof

InactiveCN107361020AEmbryonic cellsAnimal husbandryBrain vesicleCellular mechanism
The invention discloses an NTDs (neural tube defects) rat embryo animal model and a constructing method thereof. Normal pregnant rats which have been pregnant for 6 to 10 days are injected with 19-23 mg / kg of retinoic acid at one time for intragastric administration intervention, then construction of the stable and efficient NTDs rat embryo animal mode can be induced rapidly after pregnant 10.5 days, and further, rat embryo brain vesicle tissue is separated out for cell culture while an NTDs cell model can be built. The animal model and the cell model constructed by the method can provide good platforms for research on NTDs molecular mechanism and cellular mechanism in vivo and vitro.
Owner:SHANXI MEDICAL UNIV

JAK/STAT pathway inhibitors and uses thereof

The role of the JAK / STAT signal transduction pathway cellular mechanisms that lead to the onset and progression of degenerative joint diseases or disorders such as osteoarthritis (OA) is disclosed. Certain known effective OA therapeutics such as hymenialdisine, debromohymenialdisine, and its variants and derivatives are shown to function as JAK3-specific inhibitors, which downregulate steady state mRNA levels of key cellular components involved in cartilage degradation. Another JAK3-specific inhibitor, not previously known as an OA therapeutic, is shown to downregulate steady state mRNA levels of various cellular components involved in cartilage degradation in a manner identical to that of the known OA therapeutics.
Owner:GENZYME CORP

Compositions & methods for monitoring DNA repair

The present invention relates to DNA signatures that are characteristic of DNA that has been repaired in a cell by double strand break repair (DSBR) and that furthermore are characteristic of the specific cellular mechanism used to repair the DNA—such as homologous recombination (“HR”), non-homologous end joining (“NHEJ”), or microhomology-mediated end-joining (“MMEJ”). The present invention provides methods for identifying such DNA signatures, and also provides certain identified DNA signatures that are characteristic of DNA repair by HR, NHEJ, or MMEJ. The present invention also provides various methods and compositions that can be used to determine the presence of such DNA signatures in the genomes of living cells.
Owner:MEMORIAL SLOAN KETTERING CANCER CENT

A scalable robot torso and bionic quadruped robot

The invention discloses a scalable robot trunk and a bionic quadruped robot, comprising: a trunk link and an annular metamorphic mechanism; the trunk link connects two structurally symmetrical annular metamorphic mechanisms; the annular metamorphic mechanism consists of A plurality of first connecting rods are movably connected head-to-tail by the first connecting piece, and the second connecting rod is connected at the junction of every two first connecting rods, and only one end of each first connecting rod is connected with the second connecting rod, so The second connecting rods are movably connected through the second connecting piece; the telescopic rod is connected between the two second connecting rods in the center symmetrical position of the annular metamorphic mechanism. The present invention adopts a structurally symmetrical foldable metamorphic mechanism, two metamorphic mechanisms are connected through a trunk link to form a robot trunk, and each metamorphic mechanism adjusts the radial dimension of the robot trunk through a telescopic rod; the leg mechanism and the trunk Telescopic motion coupling, through the scaling and deformation of the torso, the distance between the legs of the robot, the height of the torso from the ground, etc. can be adjusted.
Owner:SHANDONG UNIV

Secreted neural apoptosis inhibiting proteins

A novel neuroprotectant was identified by microarray analysis that is differentially expressed between the ventricular zone and the cortex of human adult and fetal brain. The secreted protein antagonizes Wnt action in Xenopus embryos. Methods are described for modulating free radical neurotoxicity by contacting cells with the protein, treating neuronal diseases associated with free radical-mediated cell death by administering the protein, determining neuroprotective genomic targets associated with select free radical toxicity pathways by screening with the protein and using the protein to identify other compounds that modulate the biological activity of the secreted protein and the cell machinery that reacts to the secreted protein.
Owner:AVENTIS PHARMA INC

Methods and compositions for screening molecular function comprising chimeric minimotifs

Disclosed herein are novel compositions and methods for elucidating biological activity and detection of molecular function. The methods and compositions disclosed herein can comprise the use of one or more minimotifs and a minimotif database for integrating and coordinating orthogonal knowledge derived from a variety of technological endeavors to provide systemic models representing complex biological and molecular interactions ranging from individual cells to entire organisms. The methods and compositions disclosed herein can utilize information related to biometrics including protein / protein interaction, and gene / gene interaction for evaluating cellular functions and cellular mechanisms.
Owner:BOARD OF RGT NEVADA SYST OF HIGHER EDUCATION ON BEHALF OF THE UNIV OF NEVADA RENO

Human and murine stem-cell lines: models of endothelial cell precursors

The present invention relates to isolated human cells that are precursors of endothelial cells other than embryonic stem cells, to isolated murine cells that are precursors of endothelial cells, and to methods using same, In particular, the present invention relates to established cell lines of isolated human cells that are precursors of endothelial cells other than embryonic stem cells and established cell lines of isolated murine cells that are precursors of endothelial cells. The present invention can be used in particular in the medical and / or veterinary fields, in particular in the field of therapeutics and / or in the field of studies of cellular mechanisms.
Owner:CENT NAT DE LA RECHERCHE SCI +1

Treatment solution and method for preventing posterior capsular opacification by selectively inducing detachment and/or death of lens epithelial cells

InactiveUS20110118174A1Great incidencePrevent PCOAntibacterial agentsBiocideIon distributionLens placode
A treatment solution used to prevent posterior capsular opacification is applied or introduced into the lens capsular bag before, during, or after cataract surgery. The treatment solution may also be applied to an intraocular lens prior to surgery. The treatment solution comprises an ion transport mechanism interference agent, which either alone or in combination with other treatment agents such as an osmotic stress agent and an agent to establish a suitable pH, selectively induces detachment and / or death of lens epithelial cells such that posterior capsular opacification is prevented. While the ion transport mechanism interference agent is capable of interfering with the cellular mechanisms and cell ion distribution of a broad range of cells, a concentration of agent is selected such that the treatment solution interferes selectively with the cellular mechanisms of lens epithelial cells while leaving other ocular cells substantially unharmed. The treatment solution selectively induces cellular death and / or detachment of lens epithelial cells while other ocular cells and tissue remain substantially unharmed and without lengthy preoperative pre-treatment.
Owner:ZHANG JINJUN
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products